Adult congenital heart disease
Conditions
Interventions
None listed
Sponsors
University of Tsukuba
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Prior registration or planned registration in the database called the Japanese Network of Cardiovascular Departments for Adult Congenital Heart Disease (JNCVD-ACHD), which was established by the Japanese Society for Adult Congenital Heart Disease 2) Age over 20 years old at the time of registration between 1/1/2011 and 31/6/2019 3) Treatment with one of the following anticoagulant drugs: warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban
Exclusion criteria
Exclusion criteria: 1) Age less than 20 years old 2) Incapable of obtaining participant consent 3) Judged to be medically ineligible by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thromboembolic events and major bleeding events during administration | — |
Secondary
| Measure | Time frame |
|---|---|
| The following events during administration: 1) Minor bleeding events 2) Intracardiac thrombus 3) Other adverse events accompanying anticoagulant drug therapy 4) Changing (dose or type) or stopping anticoagulant drug therapy 5) Discontinuation of follow-up 6) Death 7) Hospitalization | — |
Countries
Japan
Contacts
Public ContactTomoko Ishizu
University of Tsukuba Department of Cardiology, Faculty of Medicine
Outcome results
None listed